| Prev Close | 306.05 |
| Day Low/High | 306.92 / 316.47 |
| 52 Wk Low/High | 138.00 / 311.29 |
Repligen Corporation (RGEN)
314.18
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 54.98B |
| Market Cap | 16.83B |
| P/E Ratio | 267.46 |
| Div & Yield | N.A. (N.A) |
Latest News
Where Does This Broad Rally Go? Q3 Earnings Begin, Amazon's Prime Day, Apple 5G
What stocks do from here will, beyond electoral risk and potential stimulus, rely upon fourth quarter guidance.
Should You Invest in Regeneron, Lilly, or Gilead?
Invest either because of their profitable portfolio, their impressive pipeline, or their technical set-up.
Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out
Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.
Markets in Limbo, Stimulus Needed, Virus in Charge, Presidential Politics
The short-term story for financial markets has been all about fiscal policy. This remains true.
Jim Cramer: What Does the Stock Market Forecast for the Economy?
The stock market is out of sync with the current economy, but it can be a forecasting machine. Let's see what it says.
3 Biotech Stocks With the Best-Looking Charts
Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.
Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019
From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.
Drug Stocks Find Trump Animus a Bitter Pill
The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.
5 Health Care Stocks Set to Bounce
These stocks are down some 20% over the last 30 months and look ripe for a rise.
Repligen Has More Upside Ahead
Add to longs on a short-term correction.
Where the Money Was Made the Last 5 Years
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
The Trader Daily
Don't batten down the hatches yet.
Some Weekend Folding Money
I'm content to head into the weekend with my short-term book mostly on the cash side.
Biotech Breakouts
Favorable charts for Celldex, Repligen and Arrowhead Research.
